Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (LGVN) reported an initial ownership filing for Jhaveri Nirav S., who serves as Chief Financial Officer. The filing shows a holding line for Class A Common Stock with 0 shares beneficially owned, as confirmed by a footnote stating that no securities are beneficially owned.
Longeveron Inc. (LGVN) is implementing a 1-for-10 reverse stock split of its Class A and Class B common stock. Stockholders approved a reverse-split range on July 1, 2026, the board set the final 1:10 ratio on July 31, 2026, and a certificate of amendment was filed in Delaware on August 20, 2026. The split becomes effective at 11:59 p.m. Eastern Time on August 26, 2026, and the Class A shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market on August 27, 2026 under the same ticker “LGVN” and a new CUSIP 54303L 302. Every ten existing shares will be combined into one share, with fractional shares rounded up at the DTC participant level and no cash paid. The split will reduce outstanding Class A shares from about 30.4 million to about 3.0 million and Class B shares from about 1.45 million to about 0.15 million, while authorized share counts and par value remain unchanged. Longeveron states the reverse split is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (symbol LGVN) reported that a director, identified as the reporting person, received an equity compensation award in the form of Class A Common Stock. On 2026-08-19, the reporting person acquired 36,000 shares through an award of time-based vesting Restricted Stock Units (RSUs) at a stated price of $0.00 per share.
After this grant, the reporting person directly holds 69,000 shares of Class A Common Stock, which the disclosure states includes RSUs subject to future vesting. The transaction is characterized as a grant, award, or other acquisition and was not reported as made pursuant to a Rule 10b5-1 trading plan.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (LGVN) director Arjun JJ Desai reported an acquisition of 36,000 shares of Class A common stock on August 19, 2026. The transaction was a grant of time-based vesting Restricted Stock Units (RSUs) at a stated price of $0.00 per share, bringing Desai’s directly held position to 36,000 shares, which includes RSUs subject to future vesting.